Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Jefferson Research
|
$20.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Neurocrine Biosciences Inc Issues FY 2013 Guidance
Neurocrine Biosciences Inc announced that for fiscal 2013, it expects revenue to approximate $3 million which consists solely of the amortization of up-front license fees and net loss to be $50 to $55 million, or $0.75 to $0.83 loss per share based on 66.5 million basic shares outstanding.
Latest Developments for Neurocrine Biosciences Inc
- Neurocrine Biosciences Inc Reaffirms FY 2013 Guidance-Conference Call
- Neurocrine Biosciences Inc Issues FY 2012 Guidance Below Analysts' Estimates
- Neurocrine Biosciences Inc Announces Exercise In Full Of Underwriters' Option To Purchase Additional Shares
- Neurocrine Biosciences Inc Announces FDA Granted Fast Track Designation For VMAT2 Inhibitor NBI-98854
Latest Key Developments in Biotechnology
- Oramed Pharmaceuticals Inc Receives FDA Clearance To Initiate Oral Insulin Trials In U.S.
- Cordlife Group Ltd Announces Proposed Acquisition Of CS Cell Technologies Pte. Ltd, Cordlife Stem Cell Technology Limited And Certain Assets Of P.T. Cordlife Indonesia From Cordlife Limited
- Stemline Therapeutics Inc Prices $60 Million Public Offering Of Common Stock
- Ambit Biosciences Corp Announces Pricing Of Initial Public Offering
- Share this
- Link this
- Digg this
Follow Reuters